Vontobel Holding
BCTX

Vontobel Holding’s Briacell Therapeutics BCTX Stock Holding History

Vontobel Holding’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-733
Closed -$62.1K – 1095
2024
Q4 		$62.1K Buy
733
+200
+38% +$24K ﹤0.01% 1060
2024
Q3 		$99.2K Buy
+533
New +$59.9K ﹤0.01% 1030

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Vontobel Holding's BCTX Position: Q1 2025 in Review

Vontobel Holding sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 733 shares — an estimated $62.1K sold.

Vontobel Holding first reported a position in BCTX in Q3 2024 and held it in 2 quarters. The position peaked at $99.2K in Q3 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Vontobel Holding reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vontobel Holding sold 733 Briacell Therapeutics shares in Q1 2025, an estimated $62.1K.
  • Vontobel Holding first reported a position in Briacell Therapeutics in Q3 2024 and held it in 2 quarters.
  • Vontobel Holding's Briacell Therapeutics position peaked at $99.2K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Vontobel Holding's 13F filing for Q1 2025, filed 28 Apr 2025.